SUMMARY Two types of intracytoplasmic inclusion were detected by immunofluorescence microscopy in 12 patients with chronic lymphocytic leukaemia and two patients with a leukaemic phase of well differentiated lymphocytic lymphoma. Further analysis with light-and electron microscopy, showed that most inclusion bodies were rod-like crystalline structures. However, in three patients they consisted of amorphous vesicular precipitates.
B chronic lymphocytic leukaemia (CLL) and lymphocytic lymphomas can in general be regarded as a neoplastic proliferation of B lymphocytes "frozen" at an immature maturation stage, characterised by the presence of surface immunoglobulins only.1
As B lymphocytes, early in their differentiation, get committed to the synthesis of an Ig with an unique VH-VL region-ie idiotype-associated with a single light chain isotype,2 a malignant B cell transformation will give rise to a malignant clone of cells each carrying identical properties when compared to the original transformed cell.
It follows that in one patient all malignant B cells synthesise identical Ig molecules. Although multiple heavy chain classes can be expressed on the same cell, the exclusive expression on one light chain isotype can be used as a criterion for monoclonality, while the idiotype has to be regarded as a tumour specific marker. 3 Several reports on patients with B-CLL have indicated that the malignant lymphocytes of some CLL patients manifest intracytoplasmic inclusion bodies consisting of monoclonal immunoglobulins. These intracytoplasmic inclusions have been obAccepted for publication 5 In our laboratory B-lymphoproliferative diseases are routinely investigated for the presence of intracellular immunoglobulins by immunofluorescence microscopy. In this way intracellular inclusions were found in 14 patients. Two different types of intracytoplasmic inclusions were observed. In most of the 14 patients the inclusions had a rod-like structure, in only three patients we observed a globular structure. On no occasion were both types of inclusions present simultaneously in the same patient. The inclusion bodies of seven patients were studied by electron microscopy. The presence of Ig containing crystals was followed in one patient during chlorambucil treatment and will be discussed in more detail. 45
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The cytoplasmic inclusions were detected by a systematic examination of the peripheral blood of patients with a B-lymphoproliferative disorder, using anti-immunoglobulin sera and cytoplasmic immunofluorescence microscopy. Further immunological and morphological studies were then carried out. The diagnosis of chronic lymphocytic leukaemia in 12 patients with intracytoplasmic inclusion bodies was made on the basis of chronic peripheral lymphocytosis (>4000 mm3) combined with infiltration of the bone marrow (>40% lymphocytes). Patients were allocated to one of the five anatomicoclinical stages as proposed by Binet et al:20 five patients belonged to stage 1 and six patients to stage 3, whereas the initial clinical findings were not available in one patient. In two other patients, intracytoplasmic inclusion bodies were seen during the leukaemic phase developing several years after the initial diagnosis of well differentiated lymphocytic lymphoma (WDLL). Lymphocyte preparations are fixed at room temperature for one hour in 2.5% glutaraldehyde in 0.075 M s-collidine buffer (pH 7-2). After overnight rinsing with 0-2 M s-collidine buffer, the cells are fixed for one hour in 1% unbuffered osmium tetroxide. Prior to dehydration they are stained with 0.5% uranyl acetate at pH 5-3 for one hour. They are embedded in Spurr resin. Ultrathin sections are contrasted with lead citrate and examined with transmission electron microscopy.
Results
Fourteen patients, expressing intracellular inclusion bodies detected by cytoplasmic immunofluorescence microscopy, were studied. The surface immunoglobulins (slg) and the immunoglobulin content of the intracellular inclusions in 14 patients are summarised in the containing an amorphous material without evident periodicity (Figs. 4, 5 ).
To evaluate the relation between inclusion positive lymphocytes and surface immunoglobulin positive lymphocytes, both cell subtypes were examined several times during the course of a chlorambucil treatment in one patient (Cla). Fig. 6 indicates that before treatment the peripheral blood lymphocyte count was 58000 mmn, of which 55% expressed sIgAlambda and 50% had crystalline inclusions. After treatment the lymphocyte count was near to normal. However, during a relapse the sIg positive lymphocytes increased again up to 43% while the relative numbers of crystal positive cells remained very low.
Discussion
This report deals with 14 cases of chronic lymphocytic leukaemia (CLL) and well differentiated lymphocytic lymphoma (WDLL) in which the malignant cells were shown to contain inclusion bodies consisting of immunoglobulins as demonstrated by immunofluorescence and electron microscopy.
In the last decade a number of reports have appeared describing this anomaly-19 2528 in B cell lymphoproliferative diseases of which CLL forms the large majority. The frequency of these inclusion bodies depends on the morphological techniques used, but can be estimated to be about 5% of all CLL patients. In this context, the intracytoplasmic immunofluorescence staining seems to be the most sensitive method. This technique confirmed the Ig 49 As already stated, the immunoglobulin content of both types of inclusion body displayed an identical heavy and light chain restriction to the one present at the surface of the malignant cells.
However, in this context it is important to note that the additional delta chain at the surface of the malignant cells of two patients was not found in the cytoplasmic inclusions. This finding was also noted in the study of Guglielmi et aP and is comparable to findings seen in morbus Waldenstrom29 3 and CLL associated with monoclonal immunoglobulins.3 ' 33 In view of our current knowledge on cellular immunoglobulin synthesis-' the former observation indicates that the Ig content of the inclusion bodies is derived from the secretion m-RNA. Indeed, during maturation of the B lymphocyte towards the secreting B cell (ie plasma cell) IgD is lost from the surface. 35 This suggests that CLL cells containing this type of inclusion body are more advanced in their maturation level and more closely related to the cells secreting a paraprotein, as is observed in about 5% of all CLL patients.6 It is unclear why the secretory Igs are precipitated in the cytoplasm. This phenomenon could be due to the inability of the Golgi apparatus to add the essential carbohydrate residues for secretion of the Ig.3' This hypothesis is supported by the PAS negativity of the inclusion bodies seen in all our patients. It is intriguing that in most of the patients reported by others and ourselves the inclusion bodies contain lambda light chain. This is in contrast to the predominance of kappa light chain on the cell surface membrane in B-CLL patients.35 Biosynthetic studies14 15 38 have shown that monoclonal Ig chains could accumulate and precipitate as crystals due to unusual physicochemical properties, possibly linked to the intracellular environment. It could be hypothesised that lambda light chain possesses such properties.
Finally, the evolution of the percentage of sIg positive and crystal positive lymphocytes of case Cla, during chlorambucil treatment, reflects a different drug sensitivity within the malignant B cell clone (Fig. 6 ). Only after a certain lapse of time the B cells will accumulate intracellular Ig, which then will precipitate as inclusion bodies. Another possibility could be that the secretory properties of the malignant B cells are affected by chorambucil. In any case, the final prognosis of patients with CLL and inclusion bodies, does not seem to differ from that of classical CLL. This was proven by the fact that all our 12 CLL patients could be classified from stage I to stage V of the anatomicoclinical classification proposed by Binet et al. 10 The clinical evolution of these patients was similar to that seen in other CLL patients.
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